Cognitive change following MPTP exposure

Neurology. 1990 Feb;40(2):261-4. doi: 10.1212/wnl.40.2.261.

Abstract

In a previous study, we demonstrated that patients with MPTP-induced parkinsonism (MPTP-IP) had a pattern of cognitive change similar to that in nondemented patients with idiopathic Parkinson's disease (PD). The present study addressed cognitive change in MPTP-exposed but relatively asymptomatic (MPTP-AS) individuals. We examined them for general intellectual function, construction, language, memory, executive function, attention, and reaction time, and compared their performance with data obtained in the previous study from patients with MPTP-IP and drug addict controls. Each MPTP-AS individual had some subtle parkinsonian signs, but in no case would these be sufficient for a diagnosis of PD. PET studies showed that these individuals had significantly reduced uptake of labeled 6-fluorodopa into the striatum. MPTP-AS and MPTP-IP groups performed comparably and were significantly worse than controls on tests of construction and category naming. The MPTP-AS group performed at a level between the other 2 groups on a test of executive function. The 3 groups performed comparably on all other measures. The similarity of the pattern of intellectual change in MPTP-AS to that seen in MPTP-IP and idiopathic PD supports the idea that the dopamine system mediates a specific set of cognitive functions and suggests that cognitive change can occur in the presence of few or no motor signs of parkinsonism.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / adverse effects*
  • Adult
  • Cognition / drug effects*
  • Humans
  • Neuropsychological Tests
  • Parkinson Disease, Secondary / chemically induced*
  • Parkinson Disease, Secondary / diagnostic imaging
  • Parkinson Disease, Secondary / physiopathology
  • Tomography, Emission-Computed

Substances

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine